Document is current
Any future updates will be listed below
-
Authors
Shinto, Eiji
Oki, Eiji
Shimokawa, Mototsugu
Yamaguchi, Shigeki
Ishiguro, Megumi
Hasegawa, Seiji
Takii, Yasumasa
Ishida, Hideyuki
Kusumoto, Tetsuya
Morita, Masaru
Tomita, Naohiro
Shiozawa, Manabu
Tanaka, Masafumi
Ozawa, Heita
Hashiguchi, Yojiro
Ohnuma, Shinobu
Tada, Sachiyo
Matsushima, Tomoko
Yamagishi, Keisuke
Hase, Kazuo
-
Funding
Funding for this research was provided by:
Sysmex Corporation
- License Information
-
More Information
Article History
Received: 31 January 2023
Accepted: 17 April 2023
First Online: 8 May 2023
Disclosure
: Eiji Oki—Speakers’ Bureau: Bayer, Chugai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Bristol-Myers. Mototsugu Shimokawa—Consulting/Advisory Role: Sysmex. Shigeki Yamaguchi—Speakers’ Bureau: Chugai Pharmaceutical, Covidien, Eli Lilly, Merck Serono, Johnson & Johnson, Taiho Pharmaceutical. Naohiro Tomita—Research Funding: Chugai Pharmaceutical, Taiho Pharmaceutical. Yojiro Hashiguchi—Honoraria: Bayer, Chugai Pharmaceutical, Kaken Pharmaceutical, Merck Serono, Sanofi, Taiho Pharmaceutical, Takeda Pharmaceutical; Research Funding: Chugai Pharmaceutical, Kaken Pharmaceutical, Merck Serono, Sanofi, Taiho Pharmaceutical, Takeda Pharmaceutical. Sachiyo Tada, Tomoko Matsushima and Keisuke Yamagishi<b>—</b>Employment: Sysmex; stock/other ownership: Sysmex. Eiji Shinto, Megumi Ishiguro, Seiji Hasegawa, Yasumasa Takii, Hideyuki Ishida, Kusumoto Tetsuya, Masaru Morita, Manabu Shiozawa, Masafumi Tanaka, Heita Ozawa, Shinobu Ohnuma, and Kazuo Hase—no relationship to disclose.
